World Journal of Diabetes最新文献

{"title":"Longitudinal effects of Johnson & Johnson COVID-19 vaccination on metabolic biomarkers in type 2 diabetes mellitus in Ethiopia.","authors":"Chala Kenenisa Edae, Abdisa Tufa Bedada, Maria Degef Teklemariam, Tibebu Girma, Solomon Genet Gebre","doi":"10.4239/wjd.v16.i6.105447","DOIUrl":"10.4239/wjd.v16.i6.105447","url":null,"abstract":"<p><strong>Background: </strong>The coronavirus disease 2019 (COVID-19) pandemic has disproportionately impacted individuals with type 2 diabetes mellitus (T2DM), increasing their risk of severe illness and mortality. Vaccination has been a crucial intervention in mitigating these risks. However, the metabolic effects of COVID-19 vaccination, particularly the Johnson & Johnson (J&J) vaccine, in diabetic populations remain inadequately explored. This study investigated the longitudinal effects of the J&J vaccine on lipid and eicosanoid biomarkers to assess its metabolic safety and potential cardiovascular benefits.</p><p><strong>Aim: </strong>To evaluate the long-term impact of the J&J COVID-19 vaccine on lipid and eicosanoid biomarkers in Ethiopian patients with T2DM.</p><p><strong>Methods: </strong>This prospective cohort study was conducted at Adama Hospital Medical College (Oromia, Ethiopia) from May 2023 to June 2024. A total of 224 T2DM patients (57 vaccinated, 167 unvaccinated) were monitored for 1 year. Biomarkers including triglycerides (TGs), high-density lipoprotein (HDL), total cholesterol (TC), prostaglandins (PGs), and thromboxanes (TXs) were measured at baseline and at 3 months, 6 months, 9 months, and 1 year post-vaccination. Statistical analyses included Generalized Estimating Equations to assess longitudinal biomarker changes.</p><p><strong>Results: </strong>TG and PG levels remained stable across all time points. HDL levels showed a temporary decline at 3 months (mean difference [MD] = -4.33; <i>P</i> < 0.001) and 6 months (MD = -2.62; <i>P</i> < 0.001) but recovered by 9 months (MD = 2.09; <i>P</i> = 0.001) and 1 year (MD = 2.38; <i>P</i> < 0.001). TC exhibited a significant decrease at 3 months (MD = -16.44, <i>P</i> = 0.001) before stabilizing. TX levels showed a consistent decline across all follow-ups (<i>e.g.,</i> 1 year: MD = -0.08; <i>P</i> = 0.036), suggesting a reduced thrombotic risk. Correlation analysis indicated significant interrelations among biomarkers, emphasizing their roles in metabolic and inflammatory pathways.</p><p><strong>Conclusion: </strong>The J&J COVID-19 vaccine exhibited metabolic safety in patients with T2DM, with transient HDL and TC reductions that later stabilized and a sustained TX decline, suggesting potential cardiovascular benefits. Further studies are needed to explore long-term immunometabolic effects on high-risk populations.</p>","PeriodicalId":48607,"journal":{"name":"World Journal of Diabetes","volume":"16 6","pages":"105447"},"PeriodicalIF":4.2,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12179887/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144477451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of negative pressure wound therapy for the treatment of diabetic foot ulcers: A meta-analysis.","authors":"Yun-Xiang Deng, Xiao-Chuan Wang, Zhen-Yu Xia, Meng-Ya Wan, Du-Yin Jiang","doi":"10.4239/wjd.v16.i6.103520","DOIUrl":"10.4239/wjd.v16.i6.103520","url":null,"abstract":"<p><strong>Background: </strong>Diabetic foot ulcers (DFUs) are a significant challenge in diabetic care, and the efficacy of negative pressure wound therapy (NPWT) in treating them remains a subject of continuous investigation.</p><p><strong>Aim: </strong>To provide a comprehensive meta-analysis of the role of NPWT in the management of DFUs.</p><p><strong>Methods: </strong>A systematic review was performed based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, searching databases like PubMed, Embase, Web of Science, and the Cochrane Library. Randomized clinical trials (RCTs) were included to compare NPWT to other dressings for DFUs. Outcomes measured were wound healing time and rate, granulation tissue formation time, amputation rate, and adverse events. Study quality was evaluated using Cochrane's risk of bias tool. Analyses utilized <i>χ</i> ², <i>I</i> ², fixed or random-effects models <i>via</i> Stata v17.</p><p><strong>Results: </strong>Of the 1101 identified articles, 9 RCTs were selected for meta-analysis. Studies spanned from 2005 to 2020 and originated from countries including the United States, Chile, Pakistan, Italy, India, and Germany. Meta-analysis demonstrated a significant improvement in wound healing rate [risk ratio (RR) = 1.46, 95%CI: 1.22-1.76, <i>P</i> < 0.01] and a reduction in amputation rate (RR = 0.69, 95%CI: 0.50-0.96, <i>P</i> = 0.006) with NPWT. Furthermore, the time for granulation tissue formation was significantly reduced by an average of 19.54 days. However, the incidence of adverse events did not significantly differ between NPWT and control treatments.</p><p><strong>Conclusion: </strong>NPWT significantly improves wound healing rates and reduces amputation rates in DFUs. It also hastens the formation of granulation tissue. However, the therapy does not significantly alter the risk of adverse events compared to alternate treatments.</p>","PeriodicalId":48607,"journal":{"name":"World Journal of Diabetes","volume":"16 6","pages":"103520"},"PeriodicalIF":4.2,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12179873/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144477440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Future of diabetic foot risk: Unveiling predictive continuous glucose monitoring biomarkers.","authors":"Haewon Byeon","doi":"10.4239/wjd.v16.i6.107006","DOIUrl":"10.4239/wjd.v16.i6.107006","url":null,"abstract":"<p><p>This study critically analyzes the findings of Geng <i>et al</i>, which investigated the association between continuous glucose monitoring (CGM) metrics and the risk of diabetic foot (DF) in individuals with type 2 diabetes mellitus. The study demonstrated significant associations between lower time in range, higher glycemic risk index, mean blood glucose, and time above range and an increased risk of DF. While acknowledging the study's strengths, such as its large sample size and robust statistical methods, this analysis also highlights its limitations, including its cross-sectional design and reliance on self-reported data. The findings are discussed within the framework of established theories, including the concepts of metabolic memory, the glucocentric paradigm, and the role of inflammation. This analysis emphasizes that a comprehensive approach to glucose management, extending beyond traditional glycated hemoglobin A1c measurements, is crucial for DF risk mitigation. Recognizing the impact of poor adherence and ongoing inflammation, future research should prioritize exploring causal mechanisms, the effectiveness of interventions aimed at improving CGM metrics, and the specific contributions of glucose variability to DF development. In conclusion, these findings strongly support the clinical application of diverse CGM metrics to enhance patient outcomes and effectively manage the risk of DF.</p>","PeriodicalId":48607,"journal":{"name":"World Journal of Diabetes","volume":"16 6","pages":"107006"},"PeriodicalIF":4.2,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12179890/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144477444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is there a role for platelet indices in predicting poor glucoregulation in type 2 diabetes mellitus?","authors":"Gabriel Araújo Medeiros, Jan B Felinto de Santana, Lenita Zajdenverg, Carlos A Negrato","doi":"10.4239/wjd.v16.i6.101173","DOIUrl":"10.4239/wjd.v16.i6.101173","url":null,"abstract":"<p><p>In this editorial, we discuss the recent article by Regassa <i>et al,</i> published in the <i>World Journal of Diabetes</i>, which highlights the potential role of platelet indices (PI) in predicting poor glucoregulation in patients with type 2 diabetes mellitus (T2DM). Given the high morbidity and mortality associated with T2DM, there is a constant need to find new and accessible methods for predicting and treating individuals with this condition. The pathophysiology of T2DM involves systemic inflammation, metabolic dysfunction, and an increased risk of vascular injury, which are commonly associated with the development of microvascular and macrovascular complications, such as cardiovascular diseases and neuropathies. The link between these complications and T2DM requires further elucidation but may be explained by prolonged exposure to high glycemic levels and increased advanced glycation end products. PI might play an important role in determining whether some individuals are prone to poor glucoregulation. Recent evidence encourages the scientific efforts to demonstrate the consistency of this role and its applicability in monitoring glucoregulation, underscoring the importance of the study by Regassa <i>et al.</i></p>","PeriodicalId":48607,"journal":{"name":"World Journal of Diabetes","volume":"16 6","pages":"101173"},"PeriodicalIF":4.2,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12179910/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144477449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond glycemic control: Roles for sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in diabetic kidney disease.","authors":"Gabriel Lc Santos, Clara Fsm Dos Santos, Gabriel R Rocha, Mariana S Calmon, Fabian Fb Lemos, Luis Go Silva, Marcel S Luz, Samuel Lr Pinheiro, Anelise Cs Botelho, Fabrício F de Melo","doi":"10.4239/wjd.v16.i6.104706","DOIUrl":"10.4239/wjd.v16.i6.104706","url":null,"abstract":"<p><p>The global prevalence of diabetes has surged in recent years, with diabetic kidney disease (DKD) emerging as a major complication. Traditional therapies have had limited success in slowing progression to end-stage kidney disease. However, novel therapies, particularly sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, which were initially developed for hyperglycemia management, have transformed the treatment of obesity, heart failure, cardiovascular disease, and more recently, DKD. SGLT2 inhibitors have consistently and significantly reduced cardiovascular events, albuminuria, and glomerular filtration rate, highlighting their efficacy across diverse clinical presentations for patients with kidney impairment. Although fewer studies have specifically investigated GLP-1 receptor agonists in patients with kidney disease, existing evidence underscores their potential to slow renal disease progression, reduce albuminuria, and improve clinically relevant outcomes. However, further research is needed to better identify patients most likely to benefit from treatment. Together, these therapies represent valuable advancements for DKD, offering significant reductions in morbidity and mortality and shifting the management of the disease by becoming essential pillars for the treatment of these patients.</p>","PeriodicalId":48607,"journal":{"name":"World Journal of Diabetes","volume":"16 6","pages":"104706"},"PeriodicalIF":4.2,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12179897/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144477436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ferroptosis: A novel therapeutic target for diabetic cardiomyopathy.","authors":"Gui-Zhi Li, Jia-Yin Liu, Hong Zhou","doi":"10.4239/wjd.v16.i6.104665","DOIUrl":"10.4239/wjd.v16.i6.104665","url":null,"abstract":"<p><p>Ferroptosis is a new type of programmed cell death caused by the accumulation of iron-dependent lipid peroxides, and it plays a role in the occurrence and progression of diverse diseases. Diabetic cardiomyopathy (DCM), a serious cardiovascular complication in patients with diabetes, eventually progresses to refractory heart failure (HF), which increases the risk of hospitalization for HF and cardiovascular death in patients with diabetes. Despite glycemic control, effective strategies to prevent DCM onset are currently lacking. Accumulating evidence suggests that ferroptosis is involved in oxidative stress, inflammation, and abnormal autophagy in diabetic myocardium, which plays an important role in myocardial apoptosis, hypertrophy, and cardiac fibrosis. The inhibition of ferroptosis can relieve DCM. Presently, ferroptosis inhibitors have been broadly suggested for the treatment of iron overload-related cardiomyopathy. This article reviewed relevant studies to offer a new therapeutic target for DCM.</p>","PeriodicalId":48607,"journal":{"name":"World Journal of Diabetes","volume":"16 6","pages":"104665"},"PeriodicalIF":4.2,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12179866/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144477443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mechanism of the epidermal growth factor receptor in promoting endothelial cell dysfunction in gestational diabetes mellitus.","authors":"Dan Tang, Cheng-Fen Wang, Jue Wang, Xiao-Tao Jing, Jing Ma","doi":"10.4239/wjd.v16.i6.105173","DOIUrl":"10.4239/wjd.v16.i6.105173","url":null,"abstract":"<p><strong>Background: </strong>Epidermal growth factor receptor (EGFR) is a transmembrane protein that is differentially expressed in gestational diabetes mellitus (GDM). Endothelial dysfunction is a hallmark of GDM and plays a key role in its pathogenesis. EGFR is associated with endothelial dysfunction in the context of various diseases. However, the exact mechanism by which EGFR causes endothelial dysfunction in GDM is unknown, particularly its regulation at the transcriptional and protein levels.</p><p><strong>Aim: </strong>To explore the molecular mechanism by which EGFR influences endothelial cell dysfunction in GDM at the transcriptional and protein levels.</p><p><strong>Methods: </strong>Quantitative real-time polymerase chain reaction was used to detect the expression of EGFR and <i>H19</i>. Western blotting was used to detect the expression of endothelial cell dysfunction markers. A cell counting kit 8 assay was used to assess cell viability, flow cytometry was used to assess apoptosis, scratch and Transwell assays were used to assess cell migration, and a tube formation assay was used to assess cell vascular formation. Hematoxylin-eosin staining was used to observe histopathological changes in the placentas of the mice.</p><p><strong>Results: </strong>In this study, EGFR was upregulated in clinical samples, GDM animal models and GDM cell models, and the knockdown of EGFR could mitigate the effect of streptozotocin (STZ) and high glucose (HG); promoted the proliferation, migration and vascularization of human umbilical vein endothelial cells (HUVECs); inhibited cell apoptosis and the expression of endothelial cell dysfunction markers (vascular cell adhesion molecule-1, tumor necrosis factor-α, vascular endothelial growth factor-A, and intercellular cell adhesion molecule-1); and alleviated the process of GDM <i>in vivo</i>. Mechanistically, <i>EIF4A3</i> binding to long noncoding RNA <i>H19</i> increased the stability of EGFR messenger RNA, thereby promoting HG-induced HUVECs dysfunction or STZ-induced endothelial cell dysfunction in GDM mice. In addition, <i>ERRFI1</i> also regulated the expression of EGFR, and <i>ERRFI1</i> inhibited EGFR activity by binding to EGFR, thereby inhibiting HG-induced HUVECs dysfunction.</p><p><strong>Conclusion: </strong>Our study revealed that EGFR can accelerate the development of GDM by promoting endothelial cell dysfunction.</p>","PeriodicalId":48607,"journal":{"name":"World Journal of Diabetes","volume":"16 6","pages":"105173"},"PeriodicalIF":4.2,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12179895/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144477364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pig bile powder maintains blood glucose homeostasis by promoting glucagon-like peptide-1 secretion <i>via</i> inhibiting farnesoid X receptor.","authors":"Yi-Min Sun, Jun-Liang Kuang, Hui-Heng Zhang, Xi-Xi Xia, Jie-Yi Wang, Dan Zheng, Ke-Jun Zhou, Ya-Jun Tang, Ai-Hua Zhao, Wei Jia, Guo-Xiang Xie, Xiao-Jiao Zheng","doi":"10.4239/wjd.v16.i6.103616","DOIUrl":"10.4239/wjd.v16.i6.103616","url":null,"abstract":"<p><strong>Background: </strong>Traditional Chinese medicine offers many valuable remedies for maintaining blood glucose homeostasis in patients with type 2 diabetes mellitus. Bile powder (BP) is a powdered form of bile derived from pigs. It has been used historically in various medicinal applications. Currently, the therapeutic potential of BP in regulating glucose homeostasis remains unclear. Bile acids (BAs) are increasingly recognized for their role in glucose metabolism particularly through the modulation of glucagon-like peptide-1 (GLP-1).</p><p><strong>Aim: </strong>To investigate BP effects on glucose homeostasis and elucidate its mechanistic role through GLP-1 and farnesoid X receptor (FXR) signaling.</p><p><strong>Methods: </strong>A diabetic mouse model was established using a high-fat diet and streptozotocin administration. Mice were treated with BP at doses of 25, 50, or 75 mg/kg/day for 45 days. Glucose homeostasis was assessed <i>via</i> the oral glucose tolerance test and insulin tolerance test. Serum GLP-1 levels were measured by enzyme-linked immunosorbent assay. A GLP-1 receptor antagonist and an FXR agonist were used to clarify the underlying mechanisms. <i>In vitro</i> STC-1 murine enteroendocrine cells were treated with a BP-mimicking BA mixture to assess GLP-1 secretion and proglucagon gene expression.</p><p><strong>Results: </strong>BP treatment significantly improved glucose homeostasis in the diabetic mouse model as indicated by lower blood glucose (<i>P</i> < 0.05) and improved insulin sensitivity. BP enhanced GLP-1 secretion (<i>P</i> < 0.05), which was an effect abolished by the GLP-1 receptor antagonist. This observation confirmed its dependence on GLP-1 signaling. In STC-1 cells, BP-derived BA mixtures stimulated GLP-1 secretion and upregulated proglucagon expression (<i>P</i> < 0.05). Mechanistically, BP inhibited FXR signaling as evidenced by the reversal of its effects upon fexaramine administration. In addition, long-term BP treatment suppressed FXR signaling, resulting in elevated GLP-1 levels and preventing glucose dysregulation.</p><p><strong>Conclusion: </strong>BP improved glucose homeostasis by promoting GLP-1 secretion <i>via</i> FXR inhibition, highlighting its potential as a therapeutic strategy for metabolic disorders.</p>","PeriodicalId":48607,"journal":{"name":"World Journal of Diabetes","volume":"16 6","pages":"103616"},"PeriodicalIF":4.2,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12179914/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144477366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends and predictors of diabetes mellitus after living kidney transplantation: A retrospective study.","authors":"Amil Huseynov, Sevim Nuran Kuşlu Çicek","doi":"10.4239/wjd.v16.i6.105069","DOIUrl":"10.4239/wjd.v16.i6.105069","url":null,"abstract":"<p><strong>Background: </strong>Post-transplant diabetes mellitus (PTDM) is a common metabolic adverse event following kidney transplantation, negatively impacting graft function and patient outcomes.</p><p><strong>Aim: </strong>To evaluate the frequency of PTDM and to determine predictive factors in living donor individuals who have undergone kidney transplantation.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 1200 living donor kidney transplant recipients treated between 2016 and 2023. Demographic, clinical, and treatment data were collected, and PTDM was identified based on American Diabetes Association criteria. Statistical analysis included logistic regression analysis to determine independent predictors of PTDM.</p><p><strong>Results: </strong>PTDM was diagnosed in 162 patients (13.5%). Risk factors included older age [odds ratio (OR) 1.03, <i>P</i> = 0.03], increased body mass index (OR 1.08, <i>P</i> = 0.02), a genetic predisposition to diabetes (OR 1.95, <i>P</i> = 0.001), and corticosteroid use (OR 1.30, <i>P</i> = 0.04). Most PTDM cases (61.7%) occurred during the initial 6 months after transplant. Tacrolimus-based regimens were more commonly associated with PTDM compared to other protocols. Renal function at 12 months was comparable between PTDM and non-PTDM groups.</p><p><strong>Conclusion: </strong>PTDM remains a significant concern in kidney transplantation, particularly among patients with modifiable risk factors. Optimizing immunosuppressive regimens, implementing early metabolic monitoring, and addressing modifiable risks such as BMI may help reduce PTDM incidence. Additional research is required to evaluate extended-term results and refine preventive strategies.</p>","PeriodicalId":48607,"journal":{"name":"World Journal of Diabetes","volume":"16 6","pages":"105069"},"PeriodicalIF":4.2,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12179902/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144477370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retroauricular subperiosteal <i>vs</i> systemic intravenous glucocorticoid administration on efficacy and blood glucose in diabetic patients with sudden deafness.","authors":"Juan Long, Hong-Wei Zuo","doi":"10.4239/wjd.v16.i6.99602","DOIUrl":"10.4239/wjd.v16.i6.99602","url":null,"abstract":"<p><strong>Background: </strong>Managing sudden deafness (SD) in patients with diabetes mellitus (DM) is particularly challenging due to the heightened risk of adverse effects associated with systemic drug administration. This study explores the potential of retroauricular subperiosteal injection as a localized drug delivery method for a more effective and safe treatment.</p><p><strong>Aim: </strong>To compare the efficacy of retroauricular subperiosteal injection <i>vs</i> systemic intravenous glucocorticoid (GC) administration for SD in patients with DM and assess the effects on blood glucose levels.</p><p><strong>Methods: </strong>A total of 128 cases of type 2 DM (T2DM) with SD diagnosed and treated in Zibo Central Hospital from February 2021 to July 2023 were divided into two groups: An observation group (66 cases receiving retroauricular subperiosteal injection of methylprednisolone) and a control group (62 cases receiving systemic intravenous administration of methylprednisolone). The two groups were compared in terms of therapeutic efficacy, hearing recovery, blood glucose level changes, and incidence of adverse reactions. Binary logistic regression was used to analyze the factors affecting therapeutic efficacy.</p><p><strong>Results: </strong>The observation group showed a significantly higher total effective rate (90.91%) compared with the control group (75.81%, <i>P</i> < 0.05). Additionally, pure-tone hearing threshold, fasting plasma glucose, and 2-hour postprandial blood glucose were significantly lower in the observation group compared with the control group (<i>P</i> < 0.05). The incidence of adverse reactions was also lower in the observation group than in the control group (7.58% <i>vs</i> 22.58%, <i>P</i> < 0.05). A T2DM course longer than 5 years and systemic intravenous GC administration were identified as independent risk factors for treatment inefficacy (<i>P</i> < 0.05).</p><p><strong>Conclusion: </strong>In treating patients with diabetes and SD, retroauricular subperiosteal injection of methylprednisolone offers superior therapeutic efficacy and lower incidence of adverse reactions compared with systemic intravenous GC administration, with minimal impact on blood glucose.</p>","PeriodicalId":48607,"journal":{"name":"World Journal of Diabetes","volume":"16 6","pages":"99602"},"PeriodicalIF":4.2,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12179903/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144477369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}